Full Press Release Details
BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the H.C. Wainwright 3rdAnnual BioConnect Investor Conference being held in New York, NY, on Tuesday, May 20, 2025.
Presentation DetailsFormat: Fireside ChatDate: Tuesday, May 20, 2025Time: 5:00 – 5:30 PM ETWebcast Link:https://journey.ct.events/view/ff005743-cd3c-4c4c-bd4d-ba8d0c84c859
The webcast of the fireside chat will be accessible in the Investor section of the CervoMed websitehttps://www.cervomed.com/.
About CervoMedCervoMed is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause clinical disease expression in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with DLB.